PROCESS FOR LYOPHILISING A PRODUCT
20200179289 ยท 2020-06-11
Inventors
Cpc classification
F26B5/06
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
A61K9/19
HUMAN NECESSITIES
F26B25/002
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
F26B25/063
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
F26B25/16
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
B65D33/00
PERFORMING OPERATIONS; TRANSPORTING
A61K9/48
HUMAN NECESSITIES
International classification
A61K9/19
HUMAN NECESSITIES
A61K9/48
HUMAN NECESSITIES
F26B25/00
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
F26B25/16
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
F26B5/06
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
Abstract
The present invention relates to a process for lyophilising a product (3), comprising the steps of providing a bulk product (3) loading system in the form of a bag (1), the bag (1) having an interior and an exterior defined by a flexible wall, the bag (1) further comprising a filling port (5) providing access to the interior of the bag (1), filling a product (3) having a first moisture content into the interior of the bag (1) via the filling port (5), and exposing the product (3) in the interior of the bag (1) to a lyophilisation cycle such that the moisture content of the product (3) is reduced from the first moisture content to a second, lower, moisture content.
Claims
1.-20. (canceled)
21. A method for lyophilizing a product comprising: a. filling a product into an interior of a bag comprising a filing port configured to provide access to the interior of the bag, wherein the interior of the bag is defined by a flexible wall of the bag, and wherein the product comprises pharmaceutical-grade live anaerobic bacterial cells having a first moisture content; and b. exposing the product to a lyophilization cycle in a lyophilizer via a portion of the bag which is open, wherein the first moisture content of the product is reduced to a second moisture content.
22. The method of claim 21, wherein the bag has two generally coplanar walls spaced apart by a side wall when filled, wherein the side wall has a substantially constant height.
23. The method of claim 21, wherein the portion of the bag which is open is the filling port, and wherein the product is exposed to the lyophilization cycle by keeping the filling port open, or by opening the filling port if the filling port was closed.
24. The method of claim 21, wherein the product is exposed to the lyophilization cycle by removing a portion of the flexible wall of the bag.
25. The method of claim 24, wherein the removing of the portion of the flexible wall of the bag is carried out after commencement of the lyophilization cycle.
26. The method of claim 21, wherein the flexible wall comprises a metallic layer.
27. The method of claim 26, wherein the metallic layer is an aluminum layer.
28. The method of claim 21, further comprising removing the product from the bag.
29. The method of claim 28, further comprising preparing a dosage form of the product.
30. The method of claim 29, wherein the preparing comprises filling a capsule with the product.
31. The method of claim 21, wherein a viability of the live anaerobic bacterial cells upon completion of the lyophilization cycle is less than two orders of magnitude lower than an initial viability of the live anaerobic bacterial cells prior to the lyophilization, as determined by an amount of colony forming units (CFU)/g of dry matter.
32. The method of claim 21, wherein a viability of the live anaerobic bacterial cells upon completion of the lyophilization cycle is less than one order of magnitude lower than an initial viability of the live anaerobic bacterial cells prior to the lyophilization, as determined by an amount of colony forming units (CFU)/g of dry matter.
33. The method of claim 21, wherein the bag further comprises a moisture permeable membrane with a water vapor transmission rate (WVTR) of at least 500 g.Math.m.sup.2.Math.d.sup.3.
34. The method of claim 21, wherein the bag has a capacity of at least 1 kg of product.
35. The method of claim 34, wherein the bag has a capacity of from about 1 kg to about 50 kg of product.
36. The method of claim 21, wherein the bag is formed of a material selected from the group consisting of: polyethylene, polyethylene terephthalate (PET), and PET-aluminium-OPA.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0088] By way of example, one or more embodiments of the present invention will now be described with reference to the accompanying drawings in which:
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
DETAILED DESCRIPTION OF THE DRAWINGS
Example 1Bulk Loading System
[0098]
[0099] As can be seen in
[0100] As can be seen from
[0101]
[0102] As is apparent from this example, the bags 1 used in the process of the present invention can be used continuously in several stages of the formulation process, from receiving and storing the moist product during storage, during lyophilisation, and during post-lyophilisation storage. Conventionally used lyophilisation trays could not be used for prolonged storage of pharmaceutical grade products, either pre- or post-lyophilisation.
Example 2Performance of Processes According to the Present Invention Versus Processes Using Conventional Lyophilisation Apparatus
[0103] Tests were conducted to evaluate the freeze drying performance of the process of the present invention as compared to processes using conventionally used apparatus. The bag of Example 1 was tested (both with its filling port opened (shown as uncut) and with part of its exterior cut away (shown as cut)) alongside a PETG plastic tray, a stainless steel tray (inox) and a Lyoguard tray. The containers were filled with water, frozen and freeze-dried for a defined period at two primary drying temperatures (10 C. and 0 C.) and two chamber pressures (150 bars and 60 bars). The water quantity was measured, which enabled evaporative capacity and the global heat transfer coefficient, Kv, to be determined for each system. The results are shown in
[0104] As can be seen, the performance of the system of the invention was comparable to that of the Lyoguard tray. Advantageously, however, the bags employed in the present invention cost only a few euros to manufacture, whereas the Lyoguard trays retail at in excess of 100 per tray. Indeed, as can be seen from
Example 3Viability of Bacterial Strains Lyophilised Using the Process of the Present Invention
[0105] Three compositions comprising separate bacterial strains (Roseburia hominis (Strain A), Bifidobacterium breve (Strain B) and Enterococcus gallinarum (Strain C)) as well as sucrose/cysteine lyoprotectants were filled into separate bags as described in Example 1 and then the bags were sealed by closing the filling ports. The contents of the bags were then frozen and the bags loaded into a freeze dryer. As this happened, the end of the bag furthest from the filling port was removed, exposing the interior of the bag, and the cut bag was then subjected to lyophilisation cycles, according to the conditions shown below:
TABLE-US-00001 Strain A Values Temperature primary desiccation(PD) 25 C. to 10 C. Vacuum PD 150 bars Temperature secondary desiccation +25 C. (SD) Vacuum SD 50 bars
TABLE-US-00002 Strain B Values Temperature primary desiccation(PD) 30 C. to 10 C. Vacuum PD 50 bars Temperature secondary desiccation +25 C. (SD) Vacuum SD 50 bars
TABLE-US-00003 Strain C Values Temperature primary desiccation(PD) 20 C. to +10 C. Vacuum PD 150 bars Temperature secondary desiccation +25 C. (SD) Vacuum SD 50 bars
[0106] Bacterial cell counts were carried out before and after lyophilisation. The results are shown in the table below:
TABLE-US-00004 Strain Viability before freeze drying Viability after freeze drying Strain A 1.10.sup.10 CFU*/g dry matter 1.10.sup.10 CFU/g dry matter Strain B 3.10.sup.11 CFU/g dry matter 1.10.sup.11 CFU/g dry matter Strain C 4.10.sup.12 CFU/g dry matter 2.10.sup.12 CFU/g dry matter *Colony Forming Units
[0107] As is apparent, the bags of Example 1 advantageously permitted three different bacterial strains to be lyophilised without any significant or unacceptable loss in viability.
[0108] It will be appreciated that the embodiments shown in the figures and described above are by way of example only, and that alterations or modifications may be made within the scope of the invention as defined in the following claims.